SCHEMBL4124786

SCHEMBL4124786

Cc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 5/20 0.74
DYRK1B Q9Y463 2/20 0.74
NPC1 O15118 10/20 0.72
RAB9A P51151 10/20 0.72
KMT2A Q03164 7/20 0.72
MEN1 O00255 6/20 0.72
MAPT P10636 5/20 0.72
SMN1; SMN2 Q16637 5/20 0.72
NFKB1 P19838 3/20 0.72
NFKB2 Q00653 3/20 0.72
RELA Q04206 3/20 0.72
POLB P06746 3/20 0.72
LMNA P02545 1/20 0.72
HDAC6 Q9UBN7 1/20 0.72
GAA P10253 1/20 0.71
LCK P06239 1/20 0.69
TDP1 Q9NUW8 2/20 0.67
USP2 O75604 1/20 0.67
OPRK1 P41145 1/20 0.62
HTT P42858 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27093077 0.91 DYRK1A (0.67) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL27093078 0.87 KDR (0.75) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL8290119 0.87 DYRK1A (0.62) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL11724806 0.85 DYRK1A (1.00) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL17001367 0.84 DYRK1A (0.74) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL18824277 0.84 DYRK1A (0.74) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL26034949 0.84 DYRK1A (0.61) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL2245925 0.84 NPC1 (0.79) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL21568324 0.84 DYRK1A (0.58) DYRK1ADYRK1BNPC1RAB9AKMT2A
SCHEMBL31206312 0.84 DYRK1A (0.62) DYRK1ANPC1RAB9AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 DYRK1A 2359/4885DYRK1B 2003/4885NPC1 927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.